Results 151 to 160 of about 49,408 (198)
Some of the next articles are maybe not open access.
Journal of Antimicrobial Chemotherapy, 1981
The stability of ceftazidime for injection in the dry state and after reconstitution with water for injections was determined. Compatibility of ceftazidime for injection with lignocaine hydrochloride injection (1.0% w/v) and several commonly used intravenous fluids was tested, Ceftazidime for injection was found to be essentially stable in the dry ...
B L, Richardson +2 more
openaire +2 more sources
The stability of ceftazidime for injection in the dry state and after reconstitution with water for injections was determined. Compatibility of ceftazidime for injection with lignocaine hydrochloride injection (1.0% w/v) and several commonly used intravenous fluids was tested, Ceftazidime for injection was found to be essentially stable in the dry ...
B L, Richardson +2 more
openaire +2 more sources
Drug Intelligence & Clinical Pharmacy, 1985
The chemistry, in vitro activity, adverse effects, and clinical indications for the new third-generation cephalosporin, ceftazidime, are reviewed. Ceftazidime appears to have a unique place among the third-generation agents in the treatment of some infectious processes caused by Pseudomonas aeruginosa. It does not demonstrate superiority to other third-
Richard L. Yost +2 more
openaire +2 more sources
The chemistry, in vitro activity, adverse effects, and clinical indications for the new third-generation cephalosporin, ceftazidime, are reviewed. Ceftazidime appears to have a unique place among the third-generation agents in the treatment of some infectious processes caused by Pseudomonas aeruginosa. It does not demonstrate superiority to other third-
Richard L. Yost +2 more
openaire +2 more sources
Journal of Antimicrobial Chemotherapy, 1983
Thirty-five patients with mean age 70 years (range 22 to 92) with 37 proven episodes of septicaemia (26) or bacteraemia (11) were treated with a mean ceftazidime dose of 1.80 (range 1 to 2 g) bid for 12 (range 3 to 17) days. Twenty patients had underlying diseases. Escherichia coli was the most common pathogen (19/37).
P, Lundbergh +3 more
openaire +2 more sources
Thirty-five patients with mean age 70 years (range 22 to 92) with 37 proven episodes of septicaemia (26) or bacteraemia (11) were treated with a mean ceftazidime dose of 1.80 (range 1 to 2 g) bid for 12 (range 3 to 17) days. Twenty patients had underlying diseases. Escherichia coli was the most common pathogen (19/37).
P, Lundbergh +3 more
openaire +2 more sources
Pulmonary Penetration of Ceftazidime
Journal of Chemotherapy, 1995For an antibiotic to be effective in lower respiratory tract infections, it should be available in adequate concentrations in respiratory tissues and fluids. Cephalosporins usually achieve modest concentrations in the respiratory tract. In this study we have determined the pulmonary penetration of intramuscularly administered ceftazidime (a single dose
CAZZOLA M +5 more
openaire +3 more sources